{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T04:04:20Z","timestamp":1774497860283,"version":"3.50.1"},"reference-count":32,"publisher":"Japanese Society of Internal Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,4,15]]},"DOI":"10.2169\/internalmedicine.6063-20","type":"journal-article","created":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T22:05:25Z","timestamp":1606082725000},"page":"1159-1168","source":"Crossref","is-referenced-by-count":20,"title":["Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin\/Cyclosporine A in Immunosuppressive Therapy-na\u00efve Patients with Aplastic Anemia in Japan"],"prefix":"10.2169","volume":"60","author":[{"given":"Kazunori","family":"Imada","sequence":"first","affiliation":[{"name":"Department of Hematology, Japanese Red Cross Osaka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoshi","family":"Obara","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroatsu","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagoya Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Imajo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Okayama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Suita City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, NTT Medical Center Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhang","family":"Fanghong","sequence":"additional","affiliation":[{"name":"Novartis Pharma KK, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Hombo","sequence":"additional","affiliation":[{"name":"Novartis Pharma KK, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Tajima","sequence":"additional","affiliation":[{"name":"Novartis Pharma KK, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Kumagai","sequence":"additional","affiliation":[{"name":"Novartis Pharma KK, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Hemato-Oncology, International Medical Center, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kanazawa University Institute of Medical Pharmaceutical and Health Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Desmond R, Townsley DM, Dunbar C, Young NS. Eltrombopag in aplastic anemia. Semin Hematol 52: 31-37, 2015.","DOI":"10.1053\/j.seminhematol.2014.10.002"},{"key":"2","unstructured":"2. Townsley DM, Desmond R, Dunbar CE, Young NS. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes. Int J Hematol 98: 48-55, 2013."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mavroudi I, Pyrovolaki K, Pavlaki K, et al. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res 35: 323-328, 2011.","DOI":"10.1016\/j.leukres.2010.06.029"},{"key":"4","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1182\/blood.V84.12.4257.bloodjournal84124257","volume":"84","author":"S Nakao","year":"1994","unstructured":"4. Nakao S, Takamatsu H, Chuhjo T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood 84: 4257-4261, 1994.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"5","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V89.10.3691","volume":"89","author":"S Nakao","year":"1997","unstructured":"5. Nakao S, Takami A, Takamatsu H, et al. Isolation of a T-cell clone showing HLA-DRB1*0405-restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia. Blood 89: 3691-3699, 1997.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"6","unstructured":"6. Ohta A, Nagai M, Nishina M, Shimada N, Nakao S, Kurokawa M. Incidence of aplastic anemia in Japan: analysis of data from a nationwide registration system. Int J Epidemiol 44: i178, 2015."},{"key":"7","unstructured":"7. Clucas DB, Fox LC, Wood EM, et al. Revisiting acquired aplastic anaemia: current concepts in diagnosis and management. Intern Med J 49: 152-159, 2019."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yamazaki H, Ohta K, Iida H, et al. Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy. Int J Hematol 110: 187-196, 2019.","DOI":"10.1007\/s12185-019-02683-1"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Bacigalupo A. How I treat acquired aplastic anemia. Blood 129: 1428-1436, 2017.","DOI":"10.1182\/blood-2016-08-693481"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Scheinberg P. Activity of eltrombopag in severe aplastic anemia. Blood Adv 2: 3054-3062, 2018.","DOI":"10.1182\/bloodadvances.2018020248"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Erickson-Miller CL, Kirchner J, Aivado M, May R, Payne P, Chadderton A. Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leuk Res 34: 1224-1231, 2010.","DOI":"10.1016\/j.leukres.2010.02.005"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sun H, Tsai Y, Nowak I, Liesveld J, Chen Y. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem\/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. Stem Cell Res 9: 77-86, 2012.","DOI":"10.1016\/j.scr.2012.05.001"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 367: 11-19, 2012.","DOI":"10.1056\/NEJMoa1200931"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood 123: 1818-1825, 2014.","DOI":"10.1182\/blood-2013-10-534743"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med 376: 1540-1550, 2017.","DOI":"10.1056\/NEJMoa1613878"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol 51: 842-856, 2011.","DOI":"10.1177\/0091270010375427"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Shida Y, Takahashi N, Nohda S, Hirama T. Pharmacokinetics and pharmacodynamics of eltrombopag in healthy Japanese men. Jpn J Clin Pharmacol Ther 42: 11-20, 2011.","DOI":"10.3999\/jscpt.42.11"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 365: 430-438, 2011.","DOI":"10.1056\/NEJMoa1103975"},{"key":"19","unstructured":"19. Atta EH, Dias DS, Marra VL, de Azevedo AM. Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol 89: 851-859, 2010."},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Marsh JC, Bacigalupo A, Schrezenmeier H, et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood 119: 5391-5396, 2012.","DOI":"10.1182\/blood-2012-02-407684"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Yoshimi A, Niemeyer CM, Fuhrer MM, Strahm B. Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children. Blood 121: 860-861, 2013.","DOI":"10.1182\/blood-2012-10-461509"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Jeong DC, Chung NG, Cho B, et al. Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children. Haematologica 99: 664-671, 2014.","DOI":"10.3324\/haematol.2013.089268"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Najean Y; for Joint Group for the Study of Aplastic and Refractory Anemias. Long-term follow-up in patients with aplastic anemia. A study of 137 androgen-treated patients surviving more than two years. Am J Med 71: 543-551, 1981.","DOI":"10.1016\/0002-9343(81)90201-1"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Scheinberg P, Singulane CC, Barbosa LS, Scheinberg M. Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag. Clin Rheumatol 33: 1347-1349, 2014.","DOI":"10.1007\/s10067-014-2600-8"},{"key":"25","unstructured":"25. Marmont AM, Bacigalupo A, Van Lint MT, et al. Treatment of severe aplastic anemia with high-dose methylprednisolone and antilymphocyte globulin. Prog Clin Biol Res 148: 271-287, 1984."},{"key":"26","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1182\/blood.V96.6.2049","volume":"96","author":"S Kojima","year":"2000","unstructured":"26. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony- stimulating factor in children with acquired aplastic anemia. Blood 96: 2049-2054, 2000.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"27","unstructured":"27. Scheinberg P, Nunez O, Wu C, Young NS. Treatment of severe aplastic anaemia with combined immunosuppression: antithymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol 133: 606-611, 2006."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Assi R, Garcia-Manero G, Ravandi F, et al. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer 124: 4192-4201, 2018.","DOI":"10.1002\/cncr.31658"},{"key":"29","unstructured":"29. Hwang YY, Gill H, Chan TSY, Leung GMK, Cheung CYM, Kwong YL. Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting. Hematology 23: 399-404, 2018."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Sakamoto T, Obara N, Kurita N, et al. Effectiveness and safety of rabbit anti-thymocyte globulin in Japanese patients with aplastic anemia. Int J Hematol 98: 319-322, 2013.","DOI":"10.1007\/s12185-013-1418-5"},{"key":"31","unstructured":"31. Suzuki T, Kobayashi H, Kawasaki Y, et al. Efficacy of combination therapy with anti-thymocyte globulin and cyclosporine A as a first-line treatment in adult patients with aplastic anemia: a comparison of rabbit and horse formulations. Int J Hematol 104: 446-453, 2016."},{"key":"32","unstructured":"32. Hong Y, Li X, Wan B, Li N, Chen Y. Efficacy and safety of eltrombopag for aplastic anemia: a systematic review and meta-analysis. Clin Drug Investig 39: 141-156, 2019."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/8\/60_6063-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T04:04:19Z","timestamp":1618632259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/8\/60_6063-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6063-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]}}}